[1]邵毅,王怡欣,漆怡晨.糖尿病性黄斑水肿患者行玻璃体内皮质类固醇植入后眼压的监测和管理——2022年欧洲专家共识解读[J].眼科新进展,2022,42(5):337-341.[doi:10.13389/j.cnki.rao.2022.0068]
　SHAO Yi,WANG Yixin,QI Yichen.Monitoring and management of intraocular pressure after corticosteroid implantation in diabetic macular edema: interpretation of updated European experts consensus 2022[J].Recent Advances in Ophthalmology,2022,42(5):337-341.[doi:10.13389/j.cnki.rao.2022.0068]
点击复制

糖尿病性黄斑水肿患者行玻璃体内皮质类固醇植入后眼压的监测和管理——2022年欧洲专家共识解读/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
42卷
期数:
2022年5期
页码:
337-341
栏目:
述评
出版日期:
2022-05-05

文章信息/Info

Title:
Monitoring and management of intraocular pressure after corticosteroid implantation in diabetic macular edema: interpretation of updated European experts consensus 2022
作者:
邵毅; 王怡欣; 漆怡晨
330006　江西省南昌市，南昌大学第一附属医院眼科（邵毅，漆怡晨）；CF244HQ　威尔士卡迪夫市，卡迪夫大学眼科学与视觉科学系（王怡欣）
Author(s):
SHAO Yi1; WANG Yixin2; QI Yichen1
1.Department of Ophthalmology,the First Affiliated Hospital of Nanchang University,Nanchang 330006,Jiangxi Province,China
2.School of Optometry and Vision Sciences,Cardiff University,Cardiff CF244HQ,Wales
关键词:
皮质类固醇植入物; 眼压; 玻璃体内植入; 糖尿病性黄斑水肿
Keywords:
corticosteroid implant;  intraocular pressure;  intravitreal implantation;  diabetic macular edema
分类号:
R774.5
DOI:
10.13389/j.cnki.rao.2022.0068
文献标志码:
A
摘要:
向玻璃体内植入皮质类固醇药物是治疗糖尿病性黄斑水肿的有效方法，但存在引起患者高眼压的副作用。为规范皮质类固醇植入物的临床使用，一些来自欧洲各地的眼科专家近期发布了关于“糖尿病性黄斑水肿患者行玻璃体内皮质类固醇植入后眼压的监测和管理”的共识，本文对该共识进行全面解读。
Abstract:
Intravitreal corticosteroid implantation is an effective therapy for treating diabetic macular edema, but it may cause side effects such as high intraocular pressure in patients. In order to standardize the clinical use of corticosteroid implants, some European ophthalmologists have recently released a consensus on monitoring and management of intraocular pressure after corticosteroid implantation in diabetic macular edema. The consensus is fully interpreted in this paper.

参考文献/References:

［1］　KIDDEE W,TROPE G E,SHENG L A,SMITH M,STRUNGARU M,BUYS Y M.Intraocular pressure monitoring post intravitreal steroids:a systematic review［J］.Surv Ophthalmol,2013,58(4):291-310.
［2］　CAMPOCHIARO P A,BROWN D M,PEARSON A,CHEN S,BOYER D,RUIZ-MORENO J,et al.Sustained delivery fluoci-nolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema［J］.Ophthalmology,2012,119(10):2125-2132.
［3］　AUGUSTIN A J,BOPP S,FECHNER M,HOLZ F,SANDNER D,WINKGEN A M,et al.Three-year results from the Retro-IDEAL study:real-world data from diabetic macular edema(DME)patients treated with ILUVIEN?(0.19 mg fluocinolone acetonide implant)［J］.Eur J Ophthalmol,2020,30(2):382-391.
［4］　BOYER D S,YOON Y H,BELFORT R,BANDELLO F,MATURI R K,AUGUSTIN A J,et al.Three-year,randomized,sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema［J］.Ophthalmology,2014,121(10):1904-1914.
［5］　ARRIGO A,ARAGONA E,CAPONE L,DI BIASE C,LATTANZIO R,BANDELLO F.Intraocular pressure changes are predictive of ocular hypertension onset after fluocinolone acetonide implant:significant cutoffs and the role of previous DEX implant［J］.Front Med (Lausanne),2021,8:725349.
［6］　GOI F J,STALMANS I,DENIS P,NORDMANN J P,TAYLOR S,DIESTELHORST M,et al.Elevated intraocular pressure after intravitreal steroid injection in diabetic macular edema:monitoring and management［J］.Ophthalmol Ther,2016,5(1):47-61.
［7］　ZARRANZ-VENTURA J,SALA-PUIGDOLLERS A,VELAZQUEZ-VILLORIA D,FIGUERAS-ROCA M,COPETE S,DISTEFANO L,et al.Long-term probability of intraocular pressure elevation with the intravitreal dexamethasone implant in the real-world［J］.PLoS One,2019,14(1):e0209997.
［8］　ZUR D,IGLICKI M,LOEWENSTEIN A.The role of steroids in the management of diabetic macular edema［J］.Ophthalmic Res,2019,62(4):231-236.
［9］　FALLICO M,MAUGERI A,LOTERY A,LONGO A,BONFIGLIO V,RUSSO A,et al.Fluocinolone acetonide vitreous insert for chronic diabetic macular oedema:a systematic review with meta-analysis of real-world experience［J］.Sci Rep,2021,11(1):4800.
［10］　GOI F J,BARTON K,DIAS J A,DIESTELHORST M,GARCIA-FEIJOO J,HOMMER A,et al.Intravitreal corticosteroid implantation in diabetic macular edema:updated European consensus guidance on monitoring and managing intraocular pressure［J］.Ophthalmol Ther,2022,11(1):15-34.
［11］　YEMANYI F,YEMANYI F,BAIDOURI H,BURNS A R,RAGHUNATHAN V.Dexamethasone and glucocorticoid-induced matrix temporally modulate key integrins,caveolins,contractility,and stiffness in human trabecular meshwork cells［J］.Invest Ophthalmol Vis Sci,2020,61(13):16.
［12］　KUBOTA T,OKABE H,HISATOMI T,YAMAKIRI K,SAKAMOTO T,TAWARA A.Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide［J］.J Glaucoma,2006,15(2):117-119.
［13］　JOHNSON D,GOTTANKA J,FLGEL C,HOFFMANN F,FUTA R,LTJEN-DRECOLL E.Ultrastructural changes in the trabecular meshwork of human eyes treated with corticosteroids［J］.Arch Ophthalmol,1997,115(3):375-383.
［14］　STEELY H T,BROWDER S L,JULIAN M B,MIGGANS S T,WILSON K L,CLARK A F.The effects of dexamethasone on fibronectin expression in cultured human trabecular meshwork cells［J］.Invest Ophthalmol Vis Sci,1992,33(7):2242-2250.
［15］　ROHEN J W,LINNR E,WITMER R.Electron microscopic studies on the trabecular meshwork in two cases of corticosteroid-glaucoma［J］.Exp Eye Res,1973,17(1):19-31.
［16］　PHULKE S,KAUSHIK S,KAUR S,PANDAV S S.Steroid-induced glaucoma:an avoidable irreversible blindness［J］.J Curr Glaucoma Pract,2017,11(2):67-72.
［17］　VI A L,KODJIKIAN L,MALCLS A,AGARD E,VOIRIN N,EL C H,et al.Tolerance of intravitreal dexamethasone implants in patients with ocular hypertension or open-angle glaucoma［J］.Retina,2017,37(1):173-178.
［18］　MAZZARELLA S,MATEO C,FREIXES S,BURES J A,RIOS J,NAVARRO R,et al.Effect of intravitreal injection of dexamethasone 0.7 mg(Ozurdex?)on intraocular pressure in patients with macular edema［J］.Ophthalmic Res,2015,54(3):143-149.
［19］　VASCONCELOS-SANTOS D V,NEHEMY P G,SCHACHAT A P,NEHEMY M B.Secondary ocular hypertension after intravitreal injection of 4 mg of triamcinolone acetonide:incidence and risk factors［J］.Retina,2008,28(4):573-580.
［20］　ARMALY M F.Effect of corticosteroids on intraocular pressure and fluid dynamics.II.The effect of dexamethasone in the glaucomatous eye［J］.Arch Ophthalmol,1963,70:492-499.
［21］　ARMALY M F.Effect of corticosteroids on intraocular pressure and fluid dynamics.I.The effect of dexamethasone in the normal eye［J］.Arch Ophthalmol,1963,70:482-491.
［22］　MALCLS A,DOT C,VOIRIN N,VI A L,AGARD ,BELLOCQ D,et al.Safety of intravitreal dexamethasone implant (OZURDEX):the SAFODEX study.Incidence and risk factors of ocular hypertension［J］.Retina,2017,37(7):1352-1359.
［23］　CHAKRAVARTHY U,TAYLOR S R,KOCH F J.CASTRO D E,SOUSA J P,BAILEY C,et al.Changes in intraocular pressure after intravitreal fluocinolone acetonide(ILUVIEN):real-world experience in three European countries［J］.Br J Ophthalmol,2019,103(8):1072-1077.
［24］　DE MORAES C G,LIEBMANN J M,LEVIN L A.Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma［J］.Prog Retin Eye Res,2017,56:107-147.
［25］　ROBERTI G,ODDONE F,AGNIFILI L,KATSANOS A,MICHELESSI M,MASTROPASQUA L,et al.Steroid-induced glaucoma:epidemiology,pathophysiology,and clinical management［J］.Surv Ophthalmol,2020,65(4):458-472.
［26］　KERSEY J P,BROADWAY D C.Corticosteroid-induced glaucoma:a review of the literature［J］.Eye (Lond),2006,20(4):407-416.
［27］　RAZEGHINEJAD M R,KATZ L J.Steroid-induced iatrogenic glaucoma［J］.Ophthalmic Res,2012,47(2):66-80.
［28］　CHOI M Y,KWON J W.Risk factors for ocular hypertension after intravitreal dexamethasone implantation in diabetic macular edema［J］.Sci Rep,2020,10(1):13736.
［29］　BAILEY C,CHAKRAVARTHY U,LOTERY A,MENON G,TALKS J,MEDISOFT AUDIT G.Extended real-world experience with the ILUVIEN? (fluocinolone acetonide) implant in the United Kingdom:3-year results from the Medisoft? audit study［J］.Eye (Lond),2022,36(5):1012-1018.
［30］　HEMARAT K,KEMMER J D,PORCO T C,EATON A M,KHURANA R N,STEWART J M.Secondary ocular hypertension and the risk of glaucoma surgery after dexamethasone intravitreal implant in routine clinical practice［J］.Ophthalmic Surg Lasers Imaging Retina,2018,49(9):680-685.
［31］　沈燕燕,邵毅,吴晓蓉,梅锋.缓释激素植入物治疗黄斑水肿的研究进展［J］.眼科新进展,2019,39(9):891-896.
SHEN Y Y,SHAO Y,WU X R,MEI F.Slow-release hormone implants in the treatment of macular edema［J］.Rec Adv Ophthalmol,2019,39(9):891-896.
［32］　CHOI W,PARK S E,KANG H G,BYEON S H,KIM S S,KOH H J,et al.Intraocular pressure change after injection of intravitreal dexamethasone (Ozurdex) implant in Korean patients［J］.Br J Ophthalmol,2019,103(10):1380-1387.

相似文献/References:

[1]范虹 刘五存 蔡鸿英 赵堪兴.改良二极管激光睫状体光凝术治疗中晚期青光眼[J].眼科新进展,2012,32(4):000.
[2]王建萍 赵燕麟 马勇 朱涛 程燕 车选义 赵桂娥 王柯.噻吗洛尔和布林佐胺联合曲伏前列素治疗原发性开角型青光眼与高眼压患者的临床研究[J].眼科新进展,2012,32(5):000.
[3]赵宁 万超 刘宁宁 王建英 陈蕾 才娜.玻璃体切割联合超全视网膜光凝、白内障摘出术治疗新生血管性青光眼[J].眼科新进展,2012,32(6):000.
[4]马恩普 赵小钊 董良 刘苏冰 曾照年.Healaflow在青光眼小梁切除术中的应用[J].眼科新进展,2012,32(6):000.
[5]沙英 刘黎明 孙勇 王绍飞 蒋晨 阿依努尔?艾买尔 陈星.联合激光虹膜切除术术后超声乳化晶状体摘出术治疗急性闭角型青光眼持续高眼压的疗效观察[J].眼科新进展,2012,32(6):000.
[6]陈洁 王桂琴 白宗禧 洛桑 石晶 昌宏发 彭秀军.北京与西藏地区青壮年人群眼压分布特点比较[J].眼科新进展,2012,32(7):000.
[7]赵武校 蓝方方 刘伟民 黄建忠 罗武强 李志超.LASIK术后高眼压患者眼压与屈光状态之间变化关系的研究[J].眼科新进展,2012,32(11):000.
[8]叶长华 厉君 周丹 林丁.Ahmed青光眼阀植入术治疗硅油填充术后继发性青光眼的远期疗效[J].眼科新进展,2012,32(11):000.
[9]董敬民 张效房 马跃伟 王卫群 孔令训.曲伏前列素治疗原发性开角型青光眼的临床研究[J].眼科新进展,2012,32(12):000.
[10]张建华 王予东 金家岩 石荣先 李彬 晁小蕊.眼压对眼轴长度影响的实验研究[J].眼科新进展,2013,33(9):000.

备注/Memo

备注/Memo:
国家自然科学基金（编号:82160195）；中央引导地方科技发展资金（编号: 20211ZDG02003）；江西省重点研发项目（编号:20181BBG70004, 20203BBG73059）
更新日期/Last Update: 2022-05-05